The Strategic Role of Bridging Therapy in Myeloma

Clinicians recognize that disease burden at chimeric antigen receptor infusion directly dictates long-term remissions. Therefore, oncologists increasingly utilize bridging therapy in myeloma between leukapheresis and cellular delivery. Chimeric antigen receptor T-cell manufacturing typically requires several weeks of laboratory processing. During this vulnerable interval, aggressive plasma cell clones frequently expand and trigger rapid clinical deterioration. Consequently, bridging therapy serves as an essential therapeutic bridge that maintains disease control and preserves organ function. A large multicenter cohort study investigated 399 patients with relapsed or refractory multiple myeloma receiving B-cell maturation antigen directed cellular immunotherapy. Notably, 348 patients, representing 87 percent of the entire cohort, received bridging therapy prior to cell infusion. Hematologists selected these interim treatments to stabilize progressive symptoms, alleviate bone pain, and suppress rising paraprotein levels. Furthermore, effective debulking prevents irreversible physiological decline, ensuring that high-risk candidates successfully reach their scheduled infusion date. However, tumor responses to bridging interventions vary substantially among diverse drug classes. Thus, careful therapy selection remains paramount to prevent therapeutic failure and subsequent disease escape.

Baseline Characteristics and Biological Disease Burden

Patients who require interim debulking typically harbor aggressive disease biology. In this multicenter investigation, bridging recipients presented with significantly more advanced disease features than non-bridged counterparts. Specifically, these individuals exhibited markedly higher frequencies of high-risk cytogenetic abnormalities, including deletion 17p and gain 1q. Moreover, clinicians noted substantial rates of penta-class refractoriness, reflecting resistance to multiple immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. These patients also demonstrated greater baseline extramedullary involvement, elevated serum lactate dehydrogenase, and higher bone marrow plasma cell infiltration. Consequently, the clinical team faced substantial therapeutic resistance while attempting to maintain disease stability. Nevertheless, clinicians successfully managed the manufacturing gap, navigating difficult kinetic trajectories without causing therapy-limiting organ toxicities. In contrast, patients who bypassed bridging presented with indolent kinetics, permitting direct progression from apheresis to lymphodepletion. Thus, the clinical necessity for bridging strongly identifies an ultra-high-risk cohort with inferior baseline prognostic indicators. Understanding these distinct biological phenotypes enables oncologists to anticipate therapeutic hurdles and design personalized bridging interventions. Accordingly, risk stratification remains essential before initiating intermediate salvage protocols.

Comparative Efficacy Across Common Bridging Regimens

The multicenter real-world study revealed that bridging efficacy varied substantially depending on the selected therapeutic regimen. Overall, clinicians observed objective response rates differing significantly between conventional chemotherapy, targeted combinations, and emerging immunotherapies. Specifically, conventional alkylator-based chemotherapy often yielded low response rates alongside significant cumulative hematological toxicity. In contrast, novel combinations incorporating non-BCMA targeted bispecific antibodies or selinexor-based regimens produced deeper, more durable cytoreduction. Furthermore, focal radiation therapy demonstrated remarkable utility for patients with localized bone lesions or extramedullary soft-tissue masses. Radiation rapidly alleviated intractable pain, halted structural destruction, and reduced localized tumor mass without generating systemic myelosuppression. However, patients displaying diffuse, rapidly disseminating disease required aggressive systemic combination regimens. Notably, achieving an objective response, such as a partial response or very good partial response prior to lymphodepletion, correlated with superior post-infusion outcomes. Conversely, disease progression during bridging portended inferior progression-free survival. Therefore, selecting an active regimen tailored to past treatment refractoriness remains vital. Oncologists must avoid recycling agents that previously failed, favoring novel mechanisms that rapidly suppress clone proliferation.

Toxicity Mitigation and Manufacturing Interval Management

Administering bridging therapy requires meticulous safety monitoring to avoid treatment-related toxicity that could derail scheduled cell infusion. Cytopenias and opportunistic infections represent the primary risks during intensive cytoreductive maneuvers. Consequently, severe hematologic toxicity can delay lymphodepletion, allowing underlying disease clones to proliferate unchecked. To mitigate these hazards, clinicians utilize growth factors and proactive antimicrobial prophylaxis. Furthermore, multidisciplinary teams carefully time the final bridging dose to provide an adequate washout period before fludarabine and cyclophosphamide conditioning. Inappropriate timing can blunt chimeric antigen receptor T-cell expansion or aggravate cytokine release syndrome. Moreover, excessive systemic toxicity impairs performance status, increasing post-infusion intensive care admissions. The real-world study confirmed that tailored bridging regimens maintained acceptable safety without causing catastrophic attrition prior to infusion. Nevertheless, physicians must remain vigilant against prolonged neutropenia and serious bacterial or fungal pathogens. Careful patient monitoring, serial lab evaluation, and dose adjustments prevent organ damage during this critical juncture. Ultimately, successful bridging balances tumor control against treatment-related toxicities, ensuring that fragile myeloma patients arrive at cellular infusion in optimal clinical condition.

Post-Infusion Outcomes and Future Clinical Directions

Long-term clinical trajectories after cellular immunotherapy correlate directly with tumor kinetics observed during bridging. In this multicenter cohort, patients demonstrating tumor regression before lymphodepletion experienced significantly longer progression-free survival and overall survival. Conversely, patients with refractory progression during bridging encountered accelerated relapse and early mortality. Furthermore, elevated tumor burden at infusion amplified the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Consequently, effective bridging acts not merely as a temporal placeholder, but as a prognostic driver of cellular efficacy. Moving forward, clinical trials must evaluate personalized bridging algorithms incorporating novel bispecific antibodies, cereblon E3 ligase modulators, and sequential targeted therapies. In addition, rapid-manufacturing cellular platforms may shorten turnaround times from apheresis to infusion, potentially reducing bridging dependence. Nevertheless, for patients with rapidly expanding refractory myeloma, interim cytoreduction will remain an indispensable component of cellular management. Clinicians must establish standardized, evidence-based guidelines to identify the most potent debulking protocols. Ultimately, optimizing interim cytoreduction empowers cellular immunotherapy to deliver durable remissions across historically poor-prognosis populations.

Frequently Asked Questions

Why is bridging therapy necessary before CAR T-cell infusion?

Bridging therapy controls rapidly proliferating disease clones during cellular manufacturing, which frequently spans four to eight weeks. Without effective interim treatment, multiple myeloma patients risk rapid symptomatic deterioration, organ dysfunction, or spinal cord compromise. Consequently, cytoreductive bridging stabilizes clinical performance, suppresses rising paraprotein levels, and lowers total tumor burden before lymphodepletion. This strategic tumor reduction prevents premature attrition and optimizes host immunological conditions for subsequent chimeric antigen receptor T-cell expansion.

Which bridging regimens demonstrate the highest cytoreductive efficacy?

Real-world clinical data demonstrate that bridging efficacy varies significantly across therapeutic classes. Novel regimens, such as non-BCMA targeted bispecific antibodies or selinexor-based combinations, achieve superior tumor debulking compared to recycled alkylator regimens. In addition, localized radiotherapy provides rapid, effective palliation for painful solitary lesions without compounding systemic myelosuppression. Oncologists must select regimens based on previous treatment refractoriness, avoiding inactive agents while maintaining manageable hematologic toxicity before cell infusion.

Does disease progression during bridging compromise CAR T-cell safety?

Yes, disease progression during bridging strongly correlates with heightened post-infusion toxicity. Patients entering conditioning with refractory, expanding disease experience higher rates of severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Furthermore, uncontrolled tumor burden impairs immune fitness and increases early non-relapse mortality from infectious complications. Therefore, achieving disease stabilization or objective tumor regression during the bridging interval remains essential to optimize post-infusion safety and progression-free survival.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Wesener MC et al. Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma. Haematologica. 2026 Sep 03. doi: 10.3324/haematol.2026.301082. PMID: 42687830.


2. Rasche L, Krauth MT, Agis H, et al. Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma. Bone Marrow Transplant. 2026;61(5):642-644.


3. Dhakal B, Scott EC, Hansen DK, et al. Efficacy and safety of bridging therapy prior to standard-of-care B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Blood. 2025;144(Suppl 1):1025.